Vor Biopharma Inc. VOR
19.86 USD +0.61 (+3.17%)
At closeNov 3, 2026, 4:35 PM EST
20.33 +0.47 +2.37%
After hours · Nov 3, 4:35 PM ET
18.93 Day range 20.63
6.50 52-week range 26.00
- YTD
- +51.83%
- 1 year
- -11.38%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +96.4% upside
Now 19.86
- Target (low)
- 27.00
- Target (mean)
- 39.00
- Target (high)
- 50.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 9
- 2 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.81333 | -0.95 – -0.64 | 307.53 | -100.3% | 0 | 0.0% | 3 |
| Next quarter | -0.99 | -0.99 – -0.99 | -0.726 | -36.4% | 0 | 0.0% | 1 |
| Current year | -6.02 | -7.86 – -3.40 | -70.50 | +91.5% | 0 | 0.0% | 3 |
| Next year | -3.53 | -4.50 – -2.53 | -6.02 | +41.3% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | William Blair | Initiated | — | Outperform |
| Aug 12, 2026 | Wedbush | Maintained | Neutral | Neutral |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 31, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Mar 30, 2026 | Jefferies | Initiated | — | Buy |
| Mar 19, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jan 9, 2026 | Citigroup | Initiated | — | Buy |
| Dec 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 17, 2025 | TD Cowen | Initiated | — | Buy |
| Dec 9, 2025 | JP Morgan | Initiated | — | Overweight |
| Nov 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 29, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 15, 2025 | Baird | Upgrade | Neutral | Outperform |
| Aug 14, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 30, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jun 27, 2025 | Baird | Maintained | Neutral | Neutral |
| Jun 26, 2025 | Wedbush | Reiterated | Neutral | Neutral |
| May 9, 2025 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| May 9, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 21, 2025 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 21, 2025 | Stifel | Maintained | Buy | Buy |
| Mar 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 10, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 8, 2024 | Baird | Maintained | Outperform | Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 6, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Sep 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |